具有多位抑制和抗氧化特性的MAO-B抑制剂在治疗神经退行性疾病方面的潜力
Moataz A Shaldam1,2, Simone Carradori2, Francesco Melfi2
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.
Mini reviews in medicinal chemistry
|July 10, 2025
概括
具有抗氧化特性的人类单胺氧化酶 (hMAO) 抑制剂在治疗神经退行性疾病 (NDs) 方面表现有前途. 本综述探讨了各种化学支架及其对抗ND中氧化应激和炎症的机制.
科学领域:
- 神经科学是一个神经科学.
- 药用化学 医学化学
- 药理学 药理学 是一个学科.
背景情况:
- 神经退行性疾病 (NDs) 影响全球数百万人,其特点是神经元细胞死亡,通常与氧化压力有关.
- 抗氧化剂治疗正在探索,以对抗神经退行过程中的氧化损伤.
- 人类单胺氧化酶 (hMAO) 抑制剂在预防氧化应激和炎症方面显示出潜力.
研究的目的:
- 审查hMAO抑制剂治疗神经退行性疾病 (NDs) 的生物潜力.
- 提供化学支架的概述,结合抗氧化能力和hMAO抑制.
- 讨论这些化合物的作用机制和结构-活性关系 (SAR).
主要方法:
- 关于hMAO抑制剂和抗氧化化合物的科学研究的文献综述.
- 对各种化学支架的分析,包括染色体,库马林,和自然化合物.
- 对NDs的多目标导向带 (MTDL) 策略的讨论.
主要成果:
- 许多基架,如染色体,库马林,,和天然化合物 (酸,白醇,素) 展现出联合抗氧化和hMAO抑制活性.
- 详细介绍了这些支架的结构-活动关系 (SAR) 和作用机制.
- 针对hMAO和其他中枢神经系统酶 (例如,BACE-1) 的MTDL策略正在探索ND治疗.
结论:
- 具有双重hMAO抑制和抗氧化特性的化合物是神经退行性疾病的有希望的治疗剂.
- 了解这些多标配体的生物活性可以导致更有效和更具体的ND治疗.
- 对MTDL策略的进一步研究有可能促进神经退行性疾病治疗的发展.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
373
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
373
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Parkinson's Disease: Treatment
389
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389
Adrenergic Agonists: Indirect-Acting Agents
1.9K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.9K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
844
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
844


